Guilherme Nader Marta, Clinical Fellow at Dana-Farber Cancer Institute, shared a post on X:
“MARGOT trial results presented by Ada Waks at SABCS 2024.
No statistically sig pCR benefit (56% vs 46%, p=0.25) between margetuximab vs. trastuzumab in combination with paclitaxel-pertuzumab in patients with HER2+ BC and CD16 genotype FF or FV.
Follow-up continues for EFS.”
